Toward a systematic approach to opioid rotation

References

• US Department of Health and Human Services, Centers for Disease Control and PreventionHealth, United States, 2011 with Chartbook on Trends in the Health of AmericansHyattsville, MDNational Center for Health Statistics2011
   Google Scholar
• DalacorteRRRigoJCDalacorteAPain management in the elderly at the end of lifeN Am J Med Sci20113834835422171240
   PubMedGoogle Scholar
• World Health OrganizationCancer pain reliefGenevaWorld Health Organization1996 Available from: http://whqlibdoc.who.int/publications/9241544821.pdfAccessed December 5, 2012
   Google Scholar
• American Society of Anesthesiologists Task Force on Acute Pain ManagementPractice guidelines for acute pain management in the perioperative setting: an updated report by the American Society of Anesthesiologists Task Force on Acute Pain ManagementAnesthesiology200410061573158115166580
   PubMed Web of Science ®Google Scholar
• AGS Panel on Persistent Pain in Older PersonsThe management of persistent pain in older personsJ Am Geriatr Soc200250Suppl 6S205S22412067390
   PubMed Web of Science ®Google Scholar
• Management of pain in osteoarthritis and rheumatoid arthritisSimonLSLipmanAGCaudill-SlosbergMGuideline for the Management of Pain in Osteoarthritis, Rheumatoid Arthritis and Juvenile Chronic Arthritis2nd edChicago, ILAmerican Pain Society20024377
   Google Scholar
• ChouRFanciulloGJFinePGAmerican Pain Society-American Academy of Pain Medicine Opioids Guidelines PanelClinical guidelines for the use of chronic opioid therapy in chronic noncancer painJ Pain200910211313019187889
   PubMed Web of Science ®Google Scholar
• KahanMMailis-GagnonAWilsonLSrivastavaANational Opioid Use Guideline GroupCanadian guideline for safe and effective use of opioids for chronic noncancer pain: clinical summary for family physicians. Part 1: general populationCan Fam Physician2011571112571266e407e41822084455
   PubMed Web of Science ®Google Scholar
• ManchikantiLAbdiSAtluriSAmerican Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2 – guidancePain Physician201215suppl 3S67S11622786449
   PubMed Web of Science ®Google Scholar
• CepedaMSFarrarJTBaumgartenMBostonRCarrDBStromBLSide effects of opioids during short-term administration: effect of age, gender, and raceClin Pharmacol Ther200374210211212891220
   PubMed Web of Science ®Google Scholar
• LötschJvon HentigNFreynhagenRCross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centersPharmacogenet Genomics200919642943619514130
   PubMed Web of Science ®Google Scholar
• RileyJRossJRRutterDNo pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patientsSupport Care Cancer2006141566415952009
   PubMed Web of Science ®Google Scholar
• PergolizziJBögerRHBuddKOpioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone)Pain Pract20088428731318503626
   PubMedGoogle Scholar
• FinePGPortenoyRKAd Hoc Expert Panel on Evidence Review and Guidelines for Opioid RotationEstablishing “best practices” for opioid rotation: conclusions of an expert panelJ Pain Symptom Manage200938341842519735902
   PubMed Web of Science ®Google Scholar
• KahanMWilsonLMailis-GagnonASrivastavaANational Opioid Use Guideline GroupCanadian guideline for safe and effective use of opioids for chronic noncancer pain: clinical summary for family physicians. Part 2: special populationsCan Fam Physician2011571112691276e419e42822084456
   PubMed Web of Science ®Google Scholar
• ManchikantiLAbdiSAtluriSAmerican Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part I-evidence assessmentPain Physician201215suppl 3S1S6522786448
   PubMed Web of Science ®Google Scholar
• WebsterLRFinePGReview and critique of opioid rotation practices and associated risks of toxicityPain Med201213456257022458884
   PubMed Web of Science ®Google Scholar
• QuigleyCOpioid switching to improve pain relief and drug tolerabilityCochrane Database Syst Rev20043CD00484715266542
   PubMedGoogle Scholar
• VissersKCBesseKHansGDevulderJMorlionBOpioid rotation in the management of chronic pain: where is the evidence?Pain Pract2010102859320070552
   PubMed Web of Science ®Google Scholar
• DroneyJRileyJRecent advances in the use of opioids for cancer painJ Pain Res2009213515521197301
   PubMedGoogle Scholar
• GearRWMiaskowskiCGordonNCPaulSMHellerPHLevineJDKappa-opioids produce significantly greater analgesia in women than in menNat Med1996211124812508898754
   PubMed Web of Science ®Google Scholar
• ViganóABrueraESuarez-AlmazorMEAge, pain intensity, and opioid dose in patients with advanced cancerCancer1998836124412509740092
   PubMed Web of Science ®Google Scholar
• SmithHBruckenthalPImplications of opioid analgesia for medically complicated patientsDrugs Aging201027541743320450239
   PubMed Web of Science ®Google Scholar
• SmithHSOpioid metabolismMayo Clin Proc200984761362419567715
   PubMed Web of Science ®Google Scholar
• Benítez-RosarioMASalinas-MartínAAguirre-JaimeAPérez-MéndezLFeriaMMorphine-methadone opioid rotation in cancer patients: analysis of dose ratio predicting factorsJ Pain Symptom Manage20093761061106819171458
   PubMed Web of Science ®Google Scholar
• GagnonBBielechMWatanabeSWalkerPHansonJBrueraEThe use of intermittent subcutaneous injections of oxycodone for opioid rotation in patients with cancer painSupport Care Cancer19997426527010423053
   PubMed Web of Science ®Google Scholar
• HaleMEAhdiehHMaTRauckROxymorphoneERStudy Group 1Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled studyJ Pain20078217518417145204
   PubMed Web of Science ®Google Scholar
• MercadanteSCasuccioAFulfaroFSwitching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective studyJ Clin Oncol200119112898290411387363
   PubMed Web of Science ®Google Scholar
• MoritaTTakigawaCOnishiHJapan Pain, Rehabilitation, Palliative Medicine, and Psycho-Oncology (PRPP) Study GroupOpioid rotation from morphine to fentanyl in delirious cancer patients: an open-label trialJ Pain Symptom Manage20053019610316043013
   PubMed Web of Science ®Google Scholar
• NarabayashiMSaijoYTakenoshitaSOpioid rotation from oral morphine to oral oxycodone in cancer patients with intolerable adverse effects: an open-label trialJpn J Clin Oncol200838429630418326541
   PubMed Web of Science ®Google Scholar
• de StoutzNDBrueraESuarez-AlmazorMOpioid rotation for toxicity reduction in terminal cancer patientsJ Pain Symptom Manage19951053783847673770
   PubMed Web of Science ®Google Scholar
• BrueraESloanPMountBScottJSuarez-AlmazorMA randomized, double-blind, double-dummy, crossover trial comparing the safety and efficacy of oral sustained-release hydromorphone with immediate-release hydromorphone in patients with cancer pain. Canadian Palliative Care Clinical Trials GroupJ Clin Oncol1996145171317178622092
   PubMed Web of Science ®Google Scholar
• ThomsenABBeckerNEriksenJOpioid rotation in chronic non-malignant pain patients. A retrospective studyActa Anaesthesiol Scand199943991892310522739
   PubMed Web of Science ®Google Scholar
• KlokeMRappMBosseBKlokeOToxicity and/or insufficient analgesia by opioid therapy: risk factors and the impact of changing the opioid. A retrospective analysis of 273 patients observed at a single centerSupport Care Cancer20008647948611094993
   PubMed Web of Science ®Google Scholar
• MorylNSantiago-PalmaJKornickCPitfalls of opioid rotation: substituting another opioid for methadone in patients with cancer painPain200296332532811973005
   PubMed Web of Science ®Google Scholar
• DrakeRLongworthJCollinsJJOpioid rotation in children with cancerJ Palliat Med20047341942215265351
   PubMedGoogle Scholar
• FreyeEAnderson-HillemacherARitzdorfILevyJVOpioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patientsPain Pract20077212312917559481
   PubMedGoogle Scholar
• CheemaBLagmanRLWalshDA prospective study of opioid rotation in pain due to advanced cancerJ Cancer Pain Symptom Palliation2008233946
   Google Scholar
• PengPTumberPStaffordMExperience of methadone therapy in 100 consecutive chronic pain patients in a multidisciplinary pain centerPain Med20089778679418564997
   PubMed Web of Science ®Google Scholar
• GattiARealeCLuziMEffects of opioid rotation in chronic pain patients: ORTIBARN studyClin Drug Investig201030suppl 23947
   Web of Science ®Google Scholar
• KorkmazskyMGhandehariJSanchezALinHMPappagalloMFeasibility study of rapid opioid rotation and titrationPain Physician2011141718221267044
   PubMed Web of Science ®Google Scholar
• McDonnellCPehoraCCrawfordMWPCA-derived factors that may be predictive of postoperative pain in pediatric patients: a possible role for the PCA ratioJ Opioid Manag201281394422479883
   PubMedGoogle Scholar
• OldenmengerWHLieversePJJanssenPJTaalWvan der RijtCCJagerAEfficacy of opioid rotation to continuous parenteral hydromorphone in advanced cancer patients failing on other opioidsSupport Care Cancer20122081639164721861200
   PubMed Web of Science ®Google Scholar
• OstgatheCVoltzRVan AaakenAPracticability, safety, and efficacy of a “German model” for opioid conversion to oral levomethadoneSupport Care Cancer20122092105211022130587
   PubMed Web of Science ®Google Scholar
• Benítez-RosarioMAFeriaMSalinas-MartínAMartínez-CastilloLPMartín-OrtegaJJOpioid switching from transdermal fentanyl to oral methadone in patients with cancer painCancer2004101122866287315529307
   PubMed Web of Science ®Google Scholar
• ParsonsHAde la CruzMEl OstaBMethadone initiation and rotation in the outpatient setting for patients with cancer painCancer2010116252052819924788
   PubMed Web of Science ®Google Scholar
• WalkerPWPallaSPeiBLSwitching from methadone to a different opioid: what is the equianalgesic dose ratio?J Palliat Med20081181103110818980450
   PubMed Web of Science ®Google Scholar
• HanaokaKYoshimuraTTomiokaTSakataHClinical study of one-day fentanyl patch in patients with cancer pain – evaluation of the efficacy and safety in relation to treatment switch from opioid analgesic therapyMasui2011602147156 Japanese21384647
   PubMedGoogle Scholar
• KawanoCHirayamaTKuroyamaMDose conversion in opioid rotation from continuous intravenous infusion of morphine hydrochloride injection to fentanyl patch in the management of cancer painYakugaku Zasshi2011131346346721372544
   PubMed Web of Science ®Google Scholar
• LeppertWThe role of methadone in opioid rotation-a Polish experienceSupport Care Cancer200917560761219043743
   PubMed Web of Science ®Google Scholar
• DaviesDDeVlamingDHainesCMethadone analgesia for children with advanced cancerPediatr Blood Cancer200851339339718428431
   PubMed Web of Science ®Google Scholar
• BraitehFEl OstaBPalmerJLReddySKBrueraECharacteristics, findings, and outcomes of palliative care inpatient consultations at a comprehensive cancer centerJ Palliat Med200710494895517803418
   PubMed Web of Science ®Google Scholar
• ClemensKEKlaschikEClinical experience with transdermal and orally administered opioids in palliative care patients – a retrospective studyJpn J Clin Oncol200737430230917519302
   PubMed Web of Science ®Google Scholar
• KatoKMizakiTYamazakiSA study of transdermal fentanyl in cancer pain at Aichi-Cancer CenterYakugaku Zasshi2004124528729115118241
   PubMed Web of Science ®Google Scholar
• Quang-CantagrelNDWallaceMSMagnusonSKOpioid substitution to improve the effectiveness of chronic noncancer pain control: a chart reviewAnesth Analg200090493393710735802
   PubMed Web of Science ®Google Scholar
• WirzSWartenbergHCElsenCWittmannMDiederichsMNadstawekJManaging cancer pain and symptoms of outpatients by rotation to sustained-release hydromorphone: a prospective clinical trialClin J Pain200622977077517057558
   PubMed Web of Science ®Google Scholar
• GriloRMBertinPScotto di FazanoCOpioid rotation in the treatment of joint pain. A review of 67 casesJoint Bone Spine200269549149412477234
   PubMed Web of Science ®Google Scholar
• GuyattGHKellerJLJaeschkeRRosenbloomDAdachiJDNewhouseMTThe n-of-1 randomized controlled trial: clinical usefulness. Our three-year experienceAnn Intern Med199011242932992297206
   PubMed Web of Science ®Google Scholar
• FosterAMobleyEWangZComplicated pain management in a CYP450 2D6 poor metabolizerPain Pract20077435235617986163
   PubMedGoogle Scholar
• ChrubasikSJunckHZappeHAStutzkeOA survey on pain complaints and health care utilization in a German population sampleEur J Anaesthesiol19981543974089699096
   PubMed Web of Science ®Google Scholar
• American Academy of Pain MedicineAAPM facts and figures on painChicagoAmerican Academy of Pain Medicine2013 Available from: http://www.painmed.org/PatientCenter/Facts_on_Pain.aspxAccessed June 6, 2013
   Google Scholar
• OxyContin^® (oxycodone HCl extended release tablets) [prescribing information]Stamford, CTPurdue Pharma L.P.2013
   Google Scholar
• Dilaudid^® (hydromorphone HCl) [prescribing information]Stamford, CTPurdue Pharma L.P.2009
   Google Scholar
• KrantzMJMartinJStimmelBMehtaDHaigneyMCQTc interval screening in methadone treatmentAnn Intern Med2009150638739519153406
   PubMed Web of Science ®Google Scholar
• AntmanEMBennettJSDaughertyAFurbergCRobertsHTaubertKAAmerican Heart AssociationUse of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart AssociationCirculation2007115121634164217325246
   PubMed Web of Science ®Google Scholar
• BerlingIWhyteIMIsbisterGKOxycodone overdose causes naloxone responsive coma and QT prolongationQJM20131061354123023890
   PubMed Web of Science ®Google Scholar
• KornickCAKilbornMJSantiago-PalmaJQTc interval prolongation associated with intravenous methadonePain2003105349950614527710
   PubMed Web of Science ®Google Scholar
• CafieroTDi MinnoRMDi IorioCQT interval and QT dispersion during the induction of anesthesia and tracheal intubation: a comparison of remifentanil and fentanylMinerva Anestesiol201177216016521150850
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER)Guidance for Industry: Pharmacokinetics in Patients With Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and LabelingRockville, MDFood and Drug Administration2003
   Google Scholar
• US Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER)Guidance for Industry: Pharmacokinetics in Patients With Impaired Renal Function— Study Design, Data Analysis, and Impact on Dosing and LabelingRockville, MDFood and Drug Administration1998
   Google Scholar
• SmithHSThe metabolism of opioid agents and the clinical impact of their active metabolitesClin J Pain201127982483821677572
   PubMed Web of Science ®Google Scholar
• DaviesGKingswoodCStreetMPharmacokinetics of opioids in renal dysfunctionClin Pharmacokinet19963164104228968655
   PubMed Web of Science ®Google Scholar
• BögerRHRenal impairment: a challenge for opioid treatment? The role of buprenorphinePalliat Med200620suppl 1S17S2316764217
   PubMed Web of Science ®Google Scholar
• TegederILötschJGeisslingerGPharmacokinetics of opioids in liver diseaseClin Pharmacokinet1999371174010451781
   PubMed Web of Science ®Google Scholar
• US Department of Justice, Drug Enforcement AgencyThe Controlled Substances Act, 21 USC §841(b)(C) Prohibited Acts ASpringfield, VAUS Department of Justice, Drug Enforcement Agency2013 Available from: http://www.deadiversion.usdoj.gov/21cfr/21usc/841.htmAccessed June 26, 2013
   Google Scholar
• RomachMKSchoedelKASellersEMUpdate on tamper-resistant drug formulationsDrug Alcohol Depend20131301–3132323415386
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and ResearchGuidance for Industry: Abuse-Deterrent Opioids-Evaluation and LabelingSilver Spring, MDCenter for Drug Evaluation and Research (CDER)2013 Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM334743.pdfAccessed June 26, 2013
   Google Scholar
• National Opioid Use Guideline GroupCanadian guideline for safe and effective use of opioids for chronic non-cancer painCanadaNational Opioid Use Guideline Group (NOUGG)2010 Available from: http://nationalpaincentre.mcmaster.ca/opioid/Accessed September 18, 2013
   Google Scholar
• MattickRPBreenCKimberJDavoliMMethadone maintenance therapy versus no opioid replacement therapy for opioid dependenceCochrane Database Syst Rev20093CD00220919588333
   PubMed Web of Science ®Google Scholar
• WebsterLRCochellaSDasguptaNAn analysis of the root causes for opioid-related overdose deaths in the United StatesPain Med201112suppl 2S26S3521668754
   PubMed Web of Science ®Google Scholar
• EarnshawVSmithLCopenhaverMDrug addiction stigma in the context of methadone maintenance therapy: an investigation into understudied sources of stigmaInt J Ment Health Addict201311111012223956702
   PubMed Web of Science ®Google Scholar
• KrebsEEBeckerWCZerzanJBairMJMcCoyKHuiSComparative mortality among Department of Veterans Affairs patients prescribed methadone or long-acting morphine for chronic painPain201115281789179521524850
   PubMed Web of Science ®Google Scholar
• BlondellRDAshrafiounLDambraCMFoschioEMZielinskiALSalcedoDMA clinical trial comparing tapering doses of buprenorphine with steady doses for chronic pain and co-existent opioid addictionJ Addict Med20104314014620959867
   PubMed Web of Science ®Google Scholar
• SchwartzRPKellySMO’GradyKEAttitudes toward buprenorphine and methadone among opioid-dependent individualsAm J Addict200817539640118770082
   PubMed Web of Science ®Google Scholar
• CiceroTJSurrattHLInciardiJUse and misuse of buprenorphine in the management of opioid addictionJ Opioid Manag20073630230818290581
   PubMedGoogle Scholar
• ComerSDSullivanMAVosburgSKAbuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusersAddiction2010105470971820403021
   PubMed Web of Science ®Google Scholar
• YokellMAZallerNDGreenTCRichJDBuprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international reviewCurr Drug Abuse Rev201141284121466501
   PubMedGoogle Scholar
• JohansonCEArfkenCLdi MenzaSSchusterCRDiversion and abuse of buprenorphine: findings from national surveys of treatment patients and physiciansDrug Alcohol Depend20121201–319019521862241
   PubMed Web of Science ®Google Scholar
• ButlerSFFernandezKCChangAMeasuring attractiveness for abuse of prescription opioidsPain Med2010111678020002325
   PubMed Web of Science ®Google Scholar
• TrescotAMDattaSLeeMHansenHOpioid pharmacologyPain Physician200811suppl 2S133S15318443637
   PubMed Web of Science ®Google Scholar
• Al-HasaniRBruchasMRMolecular mechanisms of opioid receptor-dependent signaling and behaviorAnesthesiology201111561363138122020140
   PubMed Web of Science ®Google Scholar
• PasternakGWMultiple opiate receptors: déjà vu all over againNeuropharmacology200447suppl 131232315464147
   PubMed Web of Science ®Google Scholar
• Ultram^® ER (tramadol hydrochloride) [prescribing information]Raritan, NJOrtho-McNeil-Janssen Pharmaceuticals, Inc.2009
   Google Scholar
• VadiveluNTimchenkoAHuangYSinatraRTapentadol extended-release for treatment of chronic pain: a reviewJ Pain Res2011421121821887118
   PubMedGoogle Scholar
• McCarbergBTramadol extended-release in the management of chronic painTher Clin Risk Manag20073340141018488071
   PubMedGoogle Scholar
• MercadanteSFerreraPAdileCHigh doses of oxycodone-naloxone combination may provide poor analgesiaSupport Care Cancer20111991471147221656338
   PubMed Web of Science ®Google Scholar
• MercadanteSFulfaroFWorld Health Organization guidelines for cancer pain: a reappraisalAnn Oncol200516suppl 4iv132iv13515923413
   PubMed Web of Science ®Google Scholar
• CoffmanBLKingCDRiosGRTephlyTRThe glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268)Drug Metab Dispos199826173779443856
   PubMed Web of Science ®Google Scholar
• SmithMTNeuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolitesClin Exp Pharmacol Physiol200027752452810874511
   PubMed Web of Science ®Google Scholar
• CollerJKChristrupLLSomogyiAARole of active metabolites in the use of opioidsEur J Clin Pharmacol200965212113918958460
   PubMed Web of Science ®Google Scholar
• PergolizziJVJrLabhsetwarSAPuenpatomRAJooSBen-JosephRHSummersKHPrevalence of exposure to potential CYP450 pharmacokinetic drug-drug interactions among patients with chronic low back pain taking opioidsPain Pract201111323023920807350
   PubMed Web of Science ®Google Scholar
• GoreMSadoskyALeslieDSheehanAHSelecting an appropriate medication for treating neuropathic pain in patients with diabetes: a study using the UK and Germany Mediplus databasesPain Pract20088425326218513225
   PubMedGoogle Scholar
• Duragesic^® (fentanyl transdermal system) [prescribing information]Titusville, NJJanssen Pharmaceuticals, Inc.2012
   Google Scholar
• SaartoTWiffenPJAntidepressants for neuropathic painCochrane Database Syst Rev20074CD00545417943857
   PubMedGoogle Scholar
• WebsterLEfficacy and safety of dual-opioid therapy in acute painPain Med201213suppl 1S12S2022420602
   PubMed Web of Science ®Google Scholar
• NUCYNTA^® (tapentadol) [prescribing information]Titusville, NJJanssen Pharmaceuticals Inc.2012
   Google Scholar
• LaugsandEAJakobsenGKaasaSKlepstadPInadequate symptom control in advanced cancer patients across EuropeSupport Care Cancer201119122005201421116653
   PubMed Web of Science ®Google Scholar
• VorsangerGXiangJBionidiDPost hoc analyses of data from a 90-day clinical trial evaluating the tolerability and efficacy of tapentadol immediate release and oxycodone immediate release for the relief of moderate to severe pain in elderly and nonelderly patientsPain Res Manag201116424525122059194
   PubMed Web of Science ®Google Scholar
• ThorpeDMManagement of opioid-induced constipationCurr Pain Headache Rep20015323724011309211
   PubMedGoogle Scholar
• HolzerPAhmedzaiSHNiederleNOpioid-induced bowel dysfunction in cancer-related pain: causes, consequences, and a novel approach for its managementJ Opioid Manag20095314515119662924
   PubMedGoogle Scholar
• AllanLRicharzUSimpsonKSlappendelRTransdermal fentanyl versus sustained release oral morphine in strong-opioid naive patients with chronic low back painSpine (Phila Pa 1976)200530222484249016284584
   PubMed Web of Science ®Google Scholar
• van SeventerRSmitJMSchipperRMWicksMAZuurmondWWComparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate painCurr Med Res Opin200319645746914594516
   PubMed Web of Science ®Google Scholar
• WildJEGrondSKuperwasserBLong-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis painPain Pract201010541642720602712
   PubMed Web of Science ®Google Scholar
• LangeBKuperwasserBOkamotoAEfficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back painAdv Ther201027638139920556560
   PubMed Web of Science ®Google Scholar
• ShaheenPEWalshDLasheenWDavisMPLagmanRLOpioid equianalgesic tables: are they all equally dangerous?J Pain Symptom Manage200938340941719735901
   PubMed Web of Science ®Google Scholar
• The Sidney Kimmel Comprehensive Cancer Center At Johns HopkinsThe Hopkins Opioid ProgramBaltimore, MDJohns Hopkins2012 Available from: http://www.hopweb.org/index.cfm?cfid=4634198&cftoken=46515837Accessed August 7, 2012
   Google Scholar
• McAuleyDGlobalRPhDetroit, MIGlobalRPh2013 Available from: http://www.globalrph.com/narcoticonv.htmAccessed June 7, 2013
   Google Scholar
• Practical Pain ManagementOnline opioid calculatorMontclair, NJVertical Health Media2013 LLC. Available from: http://opioidcal-culator.practicalpainmanagement.com/Accessed June 6, 2013
   Google Scholar
• PereiraJLawlorPViganoADorganMBrueraEEquianalgesic dose ratios for opioids. A critical review and proposals for long-term dosingJ Pain Symptom Manage200122267268711495714
   PubMed Web of Science ®Google Scholar
• GourlayDLHeitHAUniversal precautions revisited: managing the inherited pain patientPain Med200910suppl 2S115S12319691682
   PubMed Web of Science ®Google Scholar
• PoulsenLArendt-NielsenLBrosenKSindrupSHThe hypoalgesic effect of tramadol in relation to CYP2D6Clin Pharmacol Ther19966066366448988065
   PubMed Web of Science ®Google Scholar
• FujitaKAndoYYamamotoWAssociation of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancerCancer Chemother Pharmacol201065225125819466410
   PubMed Web of Science ®Google Scholar
• LevranOO’HaraKPelesEABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependenceHum Mol Genet200817142219222718424454
   PubMed Web of Science ®Google Scholar
• LotschJZimmermannMDarimontJDoes the A118G polymorphism at the mu-opioid receptor gene protect against morphine-6-glucuronide toxicity?Anesthesiology200297481481912357145
   PubMed Web of Science ®Google Scholar
• KlepstadPFladvadTSkorpenFEuropean Palliative Care Research Collaborative (EPCRC); European Association for Palliative Care Research NetworkInfluence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patientsPain201115251139114521398039
   PubMed Web of Science ®Google Scholar
• FerriniFTrangTMattioliTAMorphine hyperalgesia gated through microglia-mediated disruption of neuronal Cl− homeostasisNat Neurosci201316218319223292683
   PubMed Web of Science ®Google Scholar
• SlatkinNEOpioid switching and rotation in primary care: implementation and clinical utilityCurr Med Res Opin20092592133215019601703
   PubMed Web of Science ®Google Scholar
• HallettBRChalkiadisGASuspected opioid-induced hyperalgesia in an infantBr J Anaesth2012108111611822021900
   PubMed Web of Science ®Google Scholar
• SatoMMiyamoriTKoyanagiJ2 cases of successful symptom management at home by using opioid rotation from a fentanyl preparation to a continuous subcutaneous injection of morphine hydrochloride, at a dose less than the equivalent dose based on the conversion tableGan To Kagaku Ryoho201239suppl 15860 Japanese23268901
   PubMedGoogle Scholar
• WebsterLRFinePGOverdose deaths demand a new paradigm for opioid rotationPain Med201213457157422458858
   PubMed Web of Science ®Google Scholar
• WeinerMSarantopoulosCGordonETransdermal buprenorphine controls central neuropathic painJ Opioid Manag20128641441523264319
   PubMedGoogle Scholar
• PeppinJFThe use of methadone “as needed”, is it justified?J Opioid Manag2009517919344042
   PubMedGoogle Scholar
• MatsuyamaKSatomiEUenoHA case of unresectable advanced pancreatic cancer treated by gemcitabine-based chemotherapy following cancer pain alleviation by low-dose matrix-type transdermal fentanylGan To Kagaku Ryoho200936813511353 Japanese19692777
   PubMedGoogle Scholar
• LikarRKrainerBSittlRChallenging the equipotency calculation for transdermal buprenorphine: four case studiesInt J Clin Pract200862115215618173815
   PubMed Web of Science ®Google Scholar
• OkonTRGeorgeMLFentanyl-induced neurotoxicity and paradoxic painJ Pain Symptom Manage200835332733318222628
   PubMed Web of Science ®Google Scholar
• VorobeychikYChenLBushMCMaoJImproved opioid analgesic effect following opioid dose reductionPain Med20089672472718816332
   PubMed Web of Science ®Google Scholar
• AkiyamaYIsekiMIzawaRUsefulness of fentanyl patch (Durotep) in cancer patients when rotated from morphine preparationsMasui2007563317323 Japanese17366919
   PubMedGoogle Scholar
• MorylNKoganMComfortCObbensEMethadone in the treatment of pain and terminal delirum in advanced cancer patientsPalliat Support Care20053431131717039986
   PubMedGoogle Scholar
• Muller-BuschHCLindenaGTietzeKWoskanjanSOpioid switch in palliative care, opioid choice by clinical need and opioid availabilityEur J Pain20059557157916139186
   PubMed Web of Science ®Google Scholar
• ShinjoTOkadaMThe opioid combination of transdermal fentanyl and sustained release morphine for refractory cancer pain – a case reportGan To Kagaku Ryoho2005321219972000 Japanese16282744
   PubMedGoogle Scholar
• ZimmermannCSeccarecciaDBoothCMCottrellWRotation to methadone after opioid dose escalation: how should individualization of dosing occur?J Pain Palliat Care Pharmacother2005192253116061458
   PubMedGoogle Scholar
• SchriekPTreatment of cancer-related pain with transdermal buprenorphine: a report of three casesSupport Care Cancer2004121288288415480815
   PubMed Web of Science ®Google Scholar
• DaeninckPJBrueraEReduction in constipation and laxative requirements following opioid rotation to methadone: a report of four casesJ Pain Symptom Manage199918430330910534971
   PubMed Web of Science ®Google Scholar
• BrueraEPereiraJWatanabeSBelzileMKuehnNHansonJOpioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphineCancer19967848528578756381
   PubMed Web of Science ®Google Scholar
• ViganoAFanDBrueraEIndividualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicatorsPain19966711151198895238
   PubMed Web of Science ®Google Scholar
• McCance-KatzEFSullivanLENallaniSDrug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a reviewAm J Addict201019141620132117
   PubMed Web of Science ®Google Scholar
• OverholserBRFosterDROpioid pharmacokinetic drug-drug interactionsAm J Manag Care201117suppl 11S276S28721999760
   PubMedGoogle Scholar